Oncologist : Impact Factor & More
eISSN: 1549-490XpISSN: 1083-7159
Open AccessShare this on:
Key Metrics
CiteScore 
8.5
Impact Factor
5 - 10
SNIP
1.61
Recommended pre-submission checks
Powered by 
Run standard language and technical checks to improve your manuscript – before you submit
Technical Compliance
Ensure manuscript complies with standard submission guidelines.
Language Quality
Improve clarity, grammar, and academic writing style.
A comprehensive report covering all these checks awaits you.
Oncologist Journal Specifications
| Overview | |
| Publisher | OXFORD UNIV PRESS |
| Language | English |
| Frequency | Monthly |
| Article Processing Charges | USD 3494 |
| Publication Time | 19 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Society/Institute/Sponsor | Society for Translational Oncology |
| Frequency | Monthly |
| Publication Start Year | 1996 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Editorial Review Detail | |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
View less
Planning to publish in Oncologist ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Recently Published Papers in Oncologist
Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients Receiving Immune Checkpoint Inhibitors: A Pan-Tumor Propensity-Matched Analysis.
- 8 Aug 2026
- The oncologist
Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer.
- 7 Aug 2026
- The oncologist
Empathy, access, and delays: determinants of oncology care satisfaction in Polish academic and nonacademic hospitals
- 7 Aug 2026
- The Oncologist
A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting.
- 6 Aug 2026
- The oncologist
Oncofertility in Gastrointestinal (GI) Oncology - A Pan-European study of the patient perspective.
- 5 Aug 2026
- The oncologist
Chemotherapy for Invasive Papillary Carcinoma: Survival Benefit or Patient Selection?
- 3 Aug 2026
- The oncologist
Association of SGLT2 Inhibitor Use with Clinical Outcomes in Patients Receiving Immune Checkpoint Inhibitors: A Pan-Tumor Propensity-Matched Analysis.
- 8 Aug 2026
- The oncologist
Genomic Landscape and Therapeutic Implications of ALK Fusion-Positive Colorectal Cancer.
- 7 Aug 2026
- The oncologist
Empathy, access, and delays: determinants of oncology care satisfaction in Polish academic and nonacademic hospitals
- 7 Aug 2026
- The Oncologist
A phase II study to evaluate the efficacy of commercially available molecularly matched targeted therapies in the second-line setting.
- 6 Aug 2026
- The oncologist
Oncofertility in Gastrointestinal (GI) Oncology - A Pan-European study of the patient perspective.
- 5 Aug 2026
- The oncologist
Chemotherapy for Invasive Papillary Carcinoma: Survival Benefit or Patient Selection?
- 3 Aug 2026
- The oncologist
FAQs on Oncologist
How long has Oncologist been actively publishing? 
What is the publishing frequency of Oncologist?
How many articles did Oncologist publish last year?
What is the eISSN & pISSN for Oncologist?
What is Citescore for Oncologist?
What is SNIP score for Oncologist?
Who is the publisher of Oncologist?
